Trial Profile
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 May 2022
Price :
$35
*
At a glance
- Drugs Relamorelin (Primary)
- Indications Diabetic gastroparesis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; Allergan
- 26 Mar 2022 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 09 Oct 2020 This trial has been completed in the United Kingdom, according to European Clinical Trials Database record.
- 30 Sep 2020 Status changed from active, no longer recruiting to discontinued.